In vivo, irradiated tumor cell-derived EVs were found to elicit tumor-specific CD8+ T-cell responses and significantly better protect mice from tumor development than EVs from untreated tumor cells in a prophylactic vaccination experiment [101]. The gene discussed is CD8A; the disease is neoplasm.